---
figid: PMC9240883__jitc-2022-004495f03
pmcid: PMC9240883
image_filename: jitc-2022-004495f03.jpg
figure_link: /pmc/articles/PMC9240883/figure/F3/
number: Figure 3
figure_title: ''
caption: Methylation changes. (A) Correlation of p value distribution of gene methylation
  and its expression (Red bar—positive correlation; blue bar—negative correlation)
  in 5’ UTR, TSS and gene body. (B) Gene set enrichment test of IFN alpha and IFN
  gamma (HALLMARK) pathway in groups. Clinical benefit group versus non clinical benefit
  group baseline sample. C2D8, cycle 2 day 8; IFN, interferon; 5’UTR, 5’ untranslated
  region; TSS, transcriptional start site.
article_title: Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination
  with pembrolizumab in patients with solid tumors.
citation: Dionysis Papadatos-Pastos, et al. J Immunother Cancer. 2022;10(6):e004495.
year: '2022'

doi: 10.1136/jitc-2022-004495
journal_title: Journal for Immunotherapy of Cancer
journal_nlm_ta: J Immunother Cancer
publisher_name: BMJ Publishing Group

keywords:
- drug therapy, combination
- methylation
- pembrolizumab
- guadecitabine

---
